
|Articles|October 1, 2005
NSAID approved for cataract pain
After a priority 6-month review, the FDA approved nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories), a novel nonsteroidal anti-inflammatory prodrug, for the treatment of pain and inflammation associated with cataract surgery.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
2
Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze
3
Pterygium width may help predict corneal optical disturbance
4
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
5
























